News

Press Releases
In The News
Scientific Publications And Presentations

May 19, 2022

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

April 14, 2022

Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

December 16, 2021

Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors

August 11, 2021

Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer

March 16, 2021

Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer

October 22, 2020

Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

Pharmaceutical Technology | May 20, 2022

Be Bio, Resilience to manufacture engineered B cells for rare diseases

Endpoints News | May 19, 2022

Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul

Biocentury | April 14, 2022

B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up

Boston Business Journal | April 14, 2022

Arch leads $130M round for cell therapy startup targeting cancer, rare disease

Endpoints News | April 14, 2022

ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer

Fierce Biotech | April 14, 2022

Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’

Endpoints News | October 22, 2020

Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

FierceBiotech | October 22, 2020

Be Biopharma debuts with $52M to advance engineered B-cell therapies

Boston Business Journal | October 22, 2020

Longwood, Atlas Venture inject $52M into cell therapy startup

Nature Communications | October 16, 2022

Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo

May 5, 2022

Rick Morgan, Be Bio CSO, PEGS Boston Summit: Engineered B Cells as a Novel Off-the-Shelf Oncology Therapy

Nature Reviews Immunology | October 6, 2020

Transcriptional regulation of memory B cell differentiation

Frontiers in Immunology | September 11, 2019

Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

Molecular Therapy | November 21, 2017

Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells

Trends in Cancer | December 1, 2016

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors

Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer

Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer

Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

Be Bio, Resilience to manufacture engineered B cells for rare diseases

Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul

B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up

Arch leads $130M round for cell therapy startup targeting cancer, rare disease

ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer

Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’

Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

Be Biopharma debuts with $52M to advance engineered B-cell therapies

Longwood, Atlas Venture inject $52M into cell therapy startup

Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo

Rick Morgan, Be Bio CSO, PEGS Boston Summit: Engineered B Cells as a Novel Off-the-Shelf Oncology Therapy

Transcriptional regulation of memory B cell differentiation

Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells

B lymphocytes and cancer: a love-hate relationship

Meet the people behind the headlines